An early trial of a prospective COVID-19 vaccine that will soon be tested on Canadians has found it to be safe and also prompted an immune response.
A study published Friday in the Lancet journal said the formulation from China’s CanSino Biologics Inc. needs more trials to determine whether it can actually protect against SARS-CoV-2, the virus that causes COVID-19.
But it said early trials involving 108 adults in Wuhan produced neutralizing antibodies and a response in T-cells, which protect the body from pathogens, after 28 days. The most common side effects — described as “mild” and “moderate” — were pain at the injection site, fever, fatigue and headache. (Text -CBC)